MA55609A - Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih - Google Patents

Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih

Info

Publication number
MA55609A
MA55609A MA055609A MA55609A MA55609A MA 55609 A MA55609 A MA 55609A MA 055609 A MA055609 A MA 055609A MA 55609 A MA55609 A MA 55609A MA 55609 A MA55609 A MA 55609A
Authority
MA
Morocco
Prior art keywords
codv
tri
treatment
specific
binding proteins
Prior art date
Application number
MA055609A
Other languages
English (en)
French (fr)
Inventor
Mangaiarkarasi Asokan
Christian Beil
Jochen Beninga
Joerg Birkenfeld
Mark Connors
Richard A Koup
Young Do Kwon
Peter D Kwong
Qingbo Liu
Paolo Lusso
John R Mascola
Gary J Nabel
Amarendra Pegu
Ercole Rao
Ronnie Wei
Ling Xu
Zhi-Yong Yang
Original Assignee
Sanofi Sa
The United States Of America Represented By The Sec Dep Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, The United States Of America Represented By The Sec Dep Of Health And Human Services filed Critical Sanofi Sa
Publication of MA55609A publication Critical patent/MA55609A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA055609A 2019-04-09 2020-04-08 Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih MA55609A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962831415P 2019-04-09 2019-04-09
EP19306312 2019-10-08

Publications (1)

Publication Number Publication Date
MA55609A true MA55609A (fr) 2022-02-16

Family

ID=70471109

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055609A MA55609A (fr) 2019-04-09 2020-04-08 Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih

Country Status (15)

Country Link
EP (1) EP3953384A1 (de)
JP (1) JP7676316B2 (de)
KR (1) KR20210149796A (de)
CN (1) CN114096561A (de)
AU (1) AU2020273156A1 (de)
BR (1) BR112021020346A2 (de)
CA (1) CA3136147A1 (de)
CO (1) CO2021014988A2 (de)
IL (1) IL286932A (de)
MA (1) MA55609A (de)
MX (1) MX2021012384A (de)
PH (1) PH12021500042A1 (de)
SG (1) SG11202111011SA (de)
TW (1) TW202104274A (de)
WO (1) WO2020210386A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022004881A (es) 2019-10-25 2022-05-16 Sanofi Sa Metodos para analizar el emparejamiento incorrecto de cadenas en proteinas de union multiespecificas.
TW202330594A (zh) * 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
EP4408892A4 (de) * 2021-09-29 2025-11-19 Modex Therapeutics Inc Antigenbindende polypeptide, antigenbindende polypeptidkomplexe und verfahren zur verwendung davon in hiv
CN118317979A (zh) * 2021-09-29 2024-07-09 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
WO2026047100A1 (en) * 2024-08-29 2026-03-05 Fundació Privada Institut De Recerca Sobre Immunopatologies-Caixa Irsicaixa Bispecific antibody for t cell activation for the killing of hiv infected cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
CN104080805B (zh) 2011-11-07 2017-02-22 美国政府健康及人类服务部 gp41中和性抗体及其用途
CN104271597B (zh) 2011-12-08 2018-05-25 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
WO2017011414A1 (en) * 2015-07-10 2017-01-19 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
ES2894304T3 (es) * 2015-10-25 2022-02-14 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
EP3443006B1 (de) 2016-04-13 2023-08-02 Sanofi Trispezifische und/oder dreiwertige bindungsproteine
WO2018002902A1 (en) 2016-07-01 2018-01-04 Glaxosmithkline Intellectual Property (No.2) Limited Antibody-drug conjugates and therapeutic methods using the same
CN111971299A (zh) * 2018-02-21 2020-11-20 美国政府(由卫生和人类服务部的部长所代表) HIV-1 Env的中和抗体及其用途
JP7664175B2 (ja) * 2019-04-09 2025-04-17 サノフイ 三重特異性結合性タンパク質、方法、およびその使用
JP7518286B2 (ja) * 2020-08-25 2024-07-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを標的とする多重特異性抗原結合分子及び使用方法

Also Published As

Publication number Publication date
MX2021012384A (es) 2022-02-21
SG11202111011SA (en) 2021-11-29
JP2022526826A (ja) 2022-05-26
CN114096561A (zh) 2022-02-25
JP7676316B2 (ja) 2025-05-14
IL286932A (en) 2021-10-31
CO2021014988A2 (es) 2022-01-17
EP3953384A1 (de) 2022-02-16
TW202104274A (zh) 2021-02-01
WO2020210386A1 (en) 2020-10-15
AU2020273156A1 (en) 2021-12-02
PH12021500042A1 (en) 2022-06-06
CA3136147A1 (en) 2020-10-15
BR112021020346A2 (pt) 2021-12-07
KR20210149796A (ko) 2021-12-09

Similar Documents

Publication Publication Date Title
MA42641A1 (fr) Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih
EP3746119A4 (de) Verfahren zur behandlung von krebs oder infektionen unter verwendung einer kombination eines anti-pd-1-antikörpers, eines anti-lag3-antikörpers und eines anti-tigit-antikörpers
EP4267582A4 (de) Verfahren und modifizierte nukleoside zur behandlung von coronavirusinfektionen
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
EP3838517A4 (de) Instrument für einen chirurgischen hilfsroboter
EP3830183A4 (de) Hochgereinigte und/oder modifizierte fucanzusammensetzungen zur behandlung von faseradhäsionen
MA55720A (fr) Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
IL286932A (en) Trispecific and/or trivalent binding proteins using the cross-over-dual-variable domain (codv) format for treatment of hiv infection
MA45999A (fr) Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
EP3810142A4 (de) Antiretrovirale therapien und reverse-transkriptase-inhibitoren zur behandlung von morbus alzheimer
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP4121022A4 (de) Zusammensetzungen und verfahren zur behandlung und prävention einer coronavirusinfektion
EP3313818A4 (de) Verfahren zur behandlung von kaposi-sarkom oder ksvh-induziertem lymphom unter verwendung immunmodulatorischer verbindungen und verwendungen von biomarkern
EP3902826A4 (de) Verwendung von anti-fam19a5-antikörpern zur behandlung von atherosklerose
EP3829559A4 (de) Inhibitoren von histon-deacetylase zur behandlung oder vorbeugung von hiv-infektionen
EP3471738A4 (de) Cyclische phosphonatsubstituierte nukleosidderivate und verfahren zur verwendung davon zur behandlung von viruserkrankungen
EP3639829A4 (de) Verwendung von isovalerylspiramycin i, ii und/oder iii zur herstellung eines arzneimittels zur behandlung und/oder vorbeugung von tumoren und arzneimittel
EP3710015A4 (de) Verwendung von srsf3-wirkstoffen zur behandlung und/oder prävention von neurologischen erkrankungen, krebs, bakteriellen oder viralen infektionen
EA202092229A1 (ru) Мутеины cd4 и способы их применения
EP3882267A4 (de) Anti-c-met-antikörper mit erhöhter stabilität oder antigen-bindenden fragmenten davon
EP3762014A4 (de) Verfahren zur verwendung von löslichem cd24 zur behandlung von erworbenem immunschwächesyndrom (hiv/aids)
EP3904518A4 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von krebs mit tut4/7-expressionsmodulator
EP4142728C0 (de) 6'-methoxycinchonan-9-ole zur behandlung von coronavirus-infektionen
MA54501A (fr) Nouvelles protéines de liaison spécifiques de folr1 pour le diagnostic et le traitement du cancer
EP3999187A4 (de) Langlebige t-zellen zur behandlung von hiv-infektionen